Literature DB >> 24859875

Genome-wide genotyping of acute myeloid leukemia with translocation t(9;11)(p22;q23) reveals novel recurrent genomic alterations.

Michael W M Kühn1, Lars Bullinger1, Stefan Gröschel1, Jan Krönke1, Jennifer Edelmann1, Frank G Rücker1, Karina Eiwen1, Peter Paschka1, Verena I Gaidzik1, Karlheinz Holzmann2, Richard F Schlenk1, Hartmut Döhner1, Konstanze Döhner3.   

Abstract

Entities:  

Keywords:  acute myeloid leukemia; copy number alterations; genotyping; novel recurrent genomic alterations; t(9;11)(p22;q23)

Mesh：

Year:  2014        PMID： 24859875      PMCID： PMC4116844          DOI： 10.3324/haematol.2014.105544

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

Review 1.  Array-based cytogenetic approaches in acute myeloid leukemia: clinical impact and biological insights.

Authors:  Lars Bullinger; Stefan Fröhling
Journal:  Semin Oncol       Date:  2012-02       Impact factor: 4.929

Review 2.  Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: recent insights and future directions.

Authors:  C G Mullighan; J R Downing
Journal:  Leukemia       Date:  2009-02-26       Impact factor: 11.528

3.  Single nucleotide polymorphism microarray analysis of karyotypically normal acute myeloid leukemia reveals frequent copy number neutral loss of heterozygosity.

Authors:  Anne Tyybäkinoja; Erkki Elonen; Hanna Vauhkonen; Janna Saarela; Sakari Knuutila
Journal:  Haematologica       Date:  2008-04       Impact factor: 9.941

4.  High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations.

Authors:  Michael W M Kühn; Ina Radtke; Lars Bullinger; Salil Goorha; Jinjun Cheng; Jennifer Edelmann; Juliane Gohlke; Xiaoping Su; Peter Paschka; Stanley Pounds; Jürgen Krauter; Arnold Ganser; Asmaa Quessar; Raul Ribeiro; Verena I Gaidzik; Sheila Shurtleff; Jan Krönke; Karlheinz Holzmann; Jing Ma; Richard F Schlenk; Jeffrey E Rubnitz; Konstanze Döhner; Hartmut Döhner; James R Downing
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

5.  Krüppel-like factor 5 is essential for blastocyst development and the normal self-renewal of mouse ESCs.

Authors:  Masatsugu Ema; Daisuke Mori; Hitoshi Niwa; Yoshikazu Hasegawa; Yojiro Yamanaka; Seiji Hitoshi; Junsei Mimura; Yoh-ichi Kawabe; Tomohiro Hosoya; Masanobu Morita; Daisuke Shimosato; Kazuhiko Uchida; Norio Suzuki; Jun Yanagisawa; Kazuhiro Sogawa; Janet Rossant; Masayuki Yamamoto; Satoru Takahashi; Yoshiaki Fujii-Kuriyama
Journal:  Cell Stem Cell       Date:  2008-11-06       Impact factor: 24.633

6.  Molecular cytogenetic characterization of a critical region in bands 7q35-q36 commonly deleted in malignant myeloid disorders.

Authors:  K Döhner; J Brown; U Hehmann; C Hetzel; J Stewart; G Lowther; C Scholl; S Fröhling; A Cuneo; L C Tsui; P Lichter; S W Scherer; H Döhner
Journal:  Blood       Date:  1998-12-01       Impact factor: 22.113

7.  An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes.

Authors:  J Corral; I Lavenir; H Impey; A J Warren; A Forster; T A Larson; S Bell; A N McKenzie; G King; T H Rabbitts
Journal:  Cell       Date:  1996-06-14       Impact factor: 41.582

Review 8.  Target genes discovery through copy number alteration analysis in human hepatocellular carcinoma.

Authors:  De-Leung Gu; Yen-Hsieh Chen; Jou-Ho Shih; Chi-Hung Lin; Yuh-Shan Jou; Chian-Feng Chen
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

9.  Krüppel-like factor 5 mediates cellular transformation during oncogenic KRAS-induced intestinal tumorigenesis.

Authors:  Mandayam O Nandan; Beth B McConnell; Amr M Ghaleb; Agnieszka B Bialkowska; Hongmiao Sheng; Jinyi Shao; Brian A Babbin; Sylvie Robine; Vincent W Yang
Journal:  Gastroenterology       Date:  2007-10-17       Impact factor: 22.682

10.  Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing.

Authors:  Li Ding; Timothy J Ley; David E Larson; Christopher A Miller; Daniel C Koboldt; John S Welch; Julie K Ritchey; Margaret A Young; Tamara Lamprecht; Michael D McLellan; Joshua F McMichael; John W Wallis; Charles Lu; Dong Shen; Christopher C Harris; David J Dooling; Robert S Fulton; Lucinda L Fulton; Ken Chen; Heather Schmidt; Joelle Kalicki-Veizer; Vincent J Magrini; Lisa Cook; Sean D McGrath; Tammi L Vickery; Michael C Wendl; Sharon Heath; Mark A Watson; Daniel C Link; Michael H Tomasson; William D Shannon; Jacqueline E Payton; Shashikant Kulkarni; Peter Westervelt; Matthew J Walter; Timothy A Graubert; Elaine R Mardis; Richard K Wilson; John F DiPersio
Journal:  Nature       Date:  2012-01-11       Impact factor: 49.962
View more
  4 in total

1.  Aberrant expression of ETS1 and ETS2 proteins in cancer.

Authors:  Elizabeth A Fry; Kazushi Inoue
Journal:  Cancer Rep Rev       Date:  2018-04-23

Review 2.  Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma.

Authors:  Zofia Felicja Bielecka; Anna Małgorzata Czarnecka; Cezary Szczylik
Journal:  Front Oncol       Date:  2014-07-25       Impact factor: 6.244

3.  An uncommon t(9;11)(p24;q22) with monoallelic loss of ATM and KMT2A genes in a child with myelodysplastic syndrome/acute myeloid leukemia who evolved from Fanconi anemia.

Authors:  Viviane Lamim Lovatel; Daiane Corrêa de Souza; Tatiana Fonseca Alvarenga; Roberto R Capela de Matos; Claudia Diniz; Marcia Trindade Schramm; Juan Clinton Llerena Júnior; Maria Luiza Macedo Silva; Eliana Abdelhay; Teresa de Souza Fernandez
Journal:  Mol Cytogenet       Date:  2018-07-11       Impact factor: 2.009

4.  Induction of AML Preleukemic Fusion Genes in HSPCs and DNA Damage Response in Preleukemic Fusion Gene Positive Samples.

Authors:  Pavol Kosik; Matus Durdik; Milan Skorvaga; Daniela Klimova; Dominika Kochanova; Zlatica Cerna; Miroslav Kubes; Marek Holop; Igor Belyaev
Journal:  Antioxidants (Basel)       Date:  2021-03-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.